{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:21:03Z","timestamp":1792095663878,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Previous studies have shown inconsistent conclusions regarding the association between incretin-based therapies and the risk of developing gallbladder or biliary diseases. We conducted a meta-analysis to evaluate the risk of gallbladder or biliary diseases associated with dipeptidyl peptidase 4 inhibitors (DPP4i) in patients with type 2 diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The PubMed, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched (from inception up to March 14, 2022) for published randomized controlled trials (RCTs) that compared DPP4i with placebo or other glucose-lowering drugs in patients with type 2 diabetes. The outcomes of interest were cholecystitis, cholangitis, cholelithiasis, bile duct stones, and biliary colic. Relative risks (RRs) and 95% confidence intervals (CI) were pooled using a random-effects model. Subgroup analyses were performed according to patient age, trial duration, and types of DPP4i.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 97,150 participants from 75 eligible RCTs were included in the meta-analysis. DPP4i were associated with an increased risk of composite of gallbladder or biliary diseases (RR 1.20 [95% CI 1.01\u20131.42]) and cholecystitis (RR 1.38 [95% CI 1.08\u20131.75]). Among all included trials, DPP4i showed no association with the following manifestations of gallbladder or biliary diseases: cholelithiasis (RR 1.00 [95% CI 0.76\u20131.32]), cholangitis (RR 0.81 [95% CI 0.39\u20131.66]), bile duct stones (RR 1.08 [95% CI 0.57\u20132.05]), and biliary colic (RR 0.72 [95% CI 0.23\u20132.25]). Subgroup analyses showed that DPP4i were associated with a higher risk of cholecystitis in older patients (RR 1.37 [95% CI 1.03\u20131.83]) compared with younger patients (RR 1.08 [95% CI 0.89\u20132.18]) and in those with a longer duration of drug use (RR 1.43 [95% CI 1.08\u20131.89]) compared with shorter use (RR 1.23 [95% CI 0.74\u20132.03]).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This systematic review and meta-analysis of RCTs found that the use of DPP4i was associated with an increased risk of cholecystitis, especially in patients of advanced age or in those who were exposed to the drugs for a long period of time.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13098-022-00924-8","type":"journal-article","created":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T05:02:58Z","timestamp":1666328578000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials"],"prefix":"10.1186","volume":"14","author":[{"given":"Meng","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhuan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6169-0007","authenticated-orcid":false,"given":"Rong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"issue":"11","key":"924_CR1","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","volume":"16","author":"CF Deacon","year":"2020","unstructured":"Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642\u201353.","journal-title":"Nat Rev Endocrinol"},{"issue":"Suppl 2","key":"924_CR2","doi-asserted-by":"publisher","first-page":"S264","DOI":"10.2337\/dc11-s223","volume":"34","author":"S Cernea","year":"2011","unstructured":"Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care. 2011;34(Suppl 2):S264\u201371.","journal-title":"Diabetes Care"},{"issue":"3 Suppl","key":"924_CR3","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.amjmed.2009.12.007","volume":"123","author":"A Peters","year":"2010","unstructured":"Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med. 2010;123(3 Suppl):S28-37.","journal-title":"Am J Med"},{"issue":"10","key":"924_CR4","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","volume":"176","author":"JL Faillie","year":"2016","unstructured":"Faillie JL, Yu OH, Yin H, et al. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176(10):1474\u201381.","journal-title":"JAMA Intern Med"},{"issue":"10","key":"924_CR5","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.2337\/dc19-0415","volume":"42","author":"MA Nauck","year":"2019","unstructured":"Nauck MA, Muus Ghorbani ML, Kreiner E, et al. Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care. 2019;42(10):1912\u201320.","journal-title":"Diabetes Care"},{"issue":"5","key":"924_CR6","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","volume":"182","author":"L He","year":"2022","unstructured":"He L, Wang J, Ping F, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. Jama Intern Med. 2022;182(5):513\u20139.","journal-title":"Jama Intern Med"},{"issue":"3 Suppl","key":"924_CR7","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.amjmed.2009.12.007","volume":"123","author":"A Peters","year":"2010","unstructured":"Peters A. Incretin-based therapies: review of current clinical trial data. Am J Med. 2010;123(3 Suppl):S28-37.","journal-title":"Am J Med"},{"issue":"2","key":"924_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/jcpt.12373","volume":"41","author":"V Pizzimenti","year":"2016","unstructured":"Pizzimenti V, Giandalia A, Cucinotta D, et al. Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneo us adverse drug reaction reporting database. J Clin Pharm Ther. 2016;41(2):116\u20138.","journal-title":"J Clin Pharm Ther"},{"key":"924_CR9","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.","journal-title":"BMJ"},{"key":"924_CR10","unstructured":"Higgins JPT, Savovi\u0107 J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3. Retrieved 19 Mar 2022 from www.training.cochrane.org\/handbook."},{"key":"924_CR11","first-page":"e068882","volume":"377","author":"H Liyun","year":"2022","unstructured":"Liyun H, Wang Jialu, Ping Fan, et al. Dipeptidyl peptidase-4 inhibitors and gallbladder or biliary disease in type 2 diabetes: systematic review and pairwise and network meta-analysis of randomised controlled trials. BMJ. 2022;377:e068882.","journal-title":"BMJ."},{"issue":"11","key":"924_CR12","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1111\/j.1572-0241.2008.02189.x","volume":"103","author":"CJ Tsai","year":"2008","unstructured":"Tsai CJ, Leitzmann MF, Willett WC, et al. Macronutrients and insulin resistance in cholesterol gallstone disease. Am J Gastroenterol. 2008;103(11):2932\u20139.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"924_CR13","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jhep.2006.01.026","volume":"45","author":"F Nervi","year":"2006","unstructured":"Nervi F, Miquel JF, Alvarez M, et al. Gallbladder disease is associated with insulin resistance in a high risk Hispanic population. J Hepatol. 2006;45(2):299\u2013305.","journal-title":"J Hepatol"},{"issue":"4","key":"924_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/gut.41.4.433","volume":"41","author":"JH Siegel","year":"1997","unstructured":"Siegel JH, Kasmin FE. Biliary tract diseases in the elderly: management and outcomes. Gut. 1997;41(4):433\u20135.","journal-title":"Gut"},{"issue":"7","key":"924_CR15","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1210\/jc.2018-01008","volume":"104","author":"IM Gether","year":"2019","unstructured":"Gether IM, Nexe-Larsen C, Knop FK. New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs. J Clin Endocrinol Metab. 2019;104(7):2463\u201372.","journal-title":"J Clin Endocrinol Metab"},{"key":"924_CR16","unstructured":"Xenical (orlistat). Highlights of prescribing information. Retrieved 2 Nov 2021 from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020766s035lbl.pdf."},{"key":"924_CR17","unstructured":"Contrave (naltrexone HCl and bupropion HCl). Highlights of prescribing information. Retrieved 2 Nov 2021 from https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/200063s013lbl.pdf."},{"key":"924_CR18","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/DMSO.S141235","volume":"10","author":"MV Sikirica","year":"2017","unstructured":"Sikirica MV, Martin AA, Wood R, et al. Reasons for discontinuation of GLP1 receptor agonists: data from a real-world cross-sectional survey of physicians and their patients with type 2 diabetes. Diabetes Metab Syndr Obes. 2017;10:403\u201312.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"924_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1080\/00325481.2020.1845534","volume":"133","author":"A Fitch","year":"2021","unstructured":"Fitch A, Ingersoll AB. Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and prac tical considerations for primary care providers. Postgrad Med. 2021;133(3):310\u20139.","journal-title":"Postgrad Med"},{"issue":"3","key":"924_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/hep.510240313","volume":"24","author":"RL Gebhard","year":"1996","unstructured":"Gebhard RL, Prigge WF, Ansel HJ, et al. The role of gallbladder emptying in gallstone formation during diet-induced rapid weight loss. Hepatology. 1996;24(3):544\u20138.","journal-title":"Hepatology"},{"issue":"1","key":"924_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s13300-012-0015-6","volume":"4","author":"M Evans","year":"2013","unstructured":"Evans M, McEwan P, O\u2019Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice. Diabetes Ther. 2013;4(1):27\u201340.","journal-title":"Diabetes Ther"},{"key":"924_CR22","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1196\/annals.1423.042","volume":"1110","author":"D Reinhold","year":"2007","unstructured":"Reinhold D, Biton A, Goihl A, et al. Dual inhibition of dipeptidyl peptidase IV and aminopeptidase N suppresses inflammatory immune responses. Ann N Y Acad Sci. 2007;1110:402\u20139.","journal-title":"Ann N Y Acad Sci"},{"issue":"13\u201314","key":"924_CR23","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.intimp.2006.07.023","volume":"6","author":"D Reinhold","year":"2006","unstructured":"Reinhold D, Biton A, Pieper S, et al. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation. Int Immunopharmacol. 2006;6(13\u201314):1935\u201342.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"924_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2337\/dc10-1771","volume":"34","author":"MJ Willemen","year":"2011","unstructured":"Willemen MJ, Mantel-Teeuwisse AK, Straus SM, et al. Use of dipeptidyl peptidase-4 inhibitors and the reporting of infections: a disproportionality analys is in the World Health Organization VigiBase. Diabetes Care. 2011;34(2):369\u201374.","journal-title":"Diabetes Care"},{"issue":"8","key":"924_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1002\/pds.4560","volume":"27","author":"T Imatoh","year":"2018","unstructured":"Imatoh T, Nishi T, Yasui M, et al. Association between dipeptidyl peptidase-4 inhibitors and urinary tract infection in elderly patients: a retrospective cohort study. Pharmacoepidemiol Drug Saf. 2018;27(8):931\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"924_CR26","doi-asserted-by":"publisher","first-page":"816164","DOI":"10.1155\/2015\/816164","volume":"2015","author":"WS Silva Junior","year":"2015","unstructured":"Silva Junior WS, Godoy-Matos AF, Kraemer-Aguiar LG. Dipeptidyl peptidase 4: a new link between diabetes mellitus and atherosclerosis. Biomed Res Int. 2015;2015:816164.","journal-title":"Biomed Res Int"},{"issue":"10","key":"924_CR27","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1080\/003655201750422710","volume":"36","author":"F Hoentjen","year":"2001","unstructured":"Hoentjen F, Hopman WP, Jansen JB. Effect of circulating peptide YY on gallbladder emptying in humans. Scand J Gastroenterol. 2001;36(10):1086\u201391.","journal-title":"Scand J Gastroenterol"},{"issue":"6","key":"924_CR28","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.molmet.2017.03.006","volume":"6","author":"B Yusta","year":"2017","unstructured":"Yusta B, Matthews D, Flock GB, et al. Glucagon-like peptide-2 promotes gallbladder refilling via a TGR5-independent, GLP-2R-dependent pathw ay. Mol Metab. 2017;6(6):503\u201311.","journal-title":"Mol Metab"},{"issue":"5","key":"924_CR29","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1210\/en.2017-00090","volume":"158","author":"A Sankoda","year":"2017","unstructured":"Sankoda A, Harada N, Iwasaki K, et al. Long-chain free fatty acid receptor GPR120 mediates oil-induced GIP secretion through CCK in male mice. Endocrinology. 2017;158(5):1172\u201380.","journal-title":"Endocrinology"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-022-00924-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-022-00924-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-022-00924-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T05:10:10Z","timestamp":1666329010000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-022-00924-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["924"],"URL":"https:\/\/doi.org\/10.1186\/s13098-022-00924-8","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,21]]},"assertion":[{"value":"24 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"153"}}